DISCLOSURE OF UNAPPROVED STATUS OF PRODUCTS DOES NOT PREVENT EXCHANGE OF INFO ON OFF-LABEL USES, FDA MAINTAINS IN REQUEST FOR COMMENTS ON CME POLICY

Disclosure of unapproved product status does not prevent the exchange of information on off-label uses, FDA maintains in a Nov. 18 Federal Register notice seeking comment on a citizen petition opposing its attempts to establish a policy on industry-sponsored continuing medical education.